Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17510 clinical trials
Featured trial
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.  

metastatic cancer
cancer
measurable disease
solid tumor
solid tumors
  • 38 views
  • 10 May, 2022
  • 13 locations
Featured trial
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

merkel cell carcinoma
metastatic cancer
cancer
measurable disease
carcinoma
  • 101 views
  • 10 May, 2022
  • 7 locations
Featured trial
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of

endometrial carcinoma
cancer
measurable disease
primary cancer
  • 295 views
  • 10 May, 2022
  • 17 locations
Featured trial
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

  • 782 views
  • 23 Nov, 2020
  • 5 locations
Featured trial
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

  • 62 views
  • 27 Apr, 2022
  • 135 locations
Featured trial
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk ratio.

EGFR
measurable disease
pembrolizumab
  • 25 views
  • 13 Oct, 2021
  • 8 locations
Featured trial
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.

Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.

cancer
neutrophil count
serum bilirubin
  • 189 views
  • 02 Sep, 2021
  • 1 location
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor

FGFR2
FGFR1
primary tumor
primary cancer
measurable disease
  • 112 views
  • 10 May, 2022
  • 50 locations
Featured trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

FGFR2
cancer
metastatic cancer
primary cancer
  • 207 views
  • 17 May, 2022
  • 146 locations
Featured trial
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

squamous non-small cell lung cancer
platinum-based chemotherapy
lung cancer
docetaxel
non-squamous non-small cell lung cancer
  • 535 views
  • 04 May, 2022
  • 143 locations